Intellia Therapeutics (NTLA) Expected to Announce Quarterly Earnings on Thursday

Intellia Therapeutics (NASDAQ:NTLA) is anticipated to issue its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect the company to announce earnings of ($1.00) per share for the quarter. Parties may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Thursday, November 6, 2025 at 8:00 AM ET.

Intellia Therapeutics (NASDAQ:NTLA) last posted its earnings results on Thursday, August 7th. The company reported ($0.99) EPS for the quarter, beating the consensus estimate of ($1.03) by $0.04. Intellia Therapeutics had a negative return on equity of 57.48% and a negative net margin of 908.48%.The firm had revenue of $14.25 million for the quarter, compared to analysts’ expectations of $12.26 million. During the same period last year, the firm earned ($1.52) EPS. The firm’s revenue was up 104.3% compared to the same quarter last year. On average, analysts expect Intellia Therapeutics to post $-5 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Intellia Therapeutics Price Performance

NTLA opened at $13.12 on Thursday. Intellia Therapeutics has a 12 month low of $5.90 and a 12 month high of $28.25. The stock has a market cap of $1.41 billion, a P/E ratio of -2.80 and a beta of 2.37. The stock’s 50 day moving average price is $17.03 and its 200 day moving average price is $12.27.

Insider Transactions at Intellia Therapeutics

In related news, Director William J. Chase purchased 100,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 20th. The shares were purchased at an average price of $10.03 per share, with a total value of $1,003,000.00. Following the purchase, the director owned 134,693 shares of the company’s stock, valued at $1,350,970.79. This trade represents a 288.24% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CAO Michael P. Dube sold 1,871 shares of Intellia Therapeutics stock in a transaction that occurred on Wednesday, October 1st. The stock was sold at an average price of $17.38, for a total transaction of $32,517.98. Following the completion of the transaction, the chief accounting officer directly owned 55,266 shares in the company, valued at approximately $960,523.08. This trade represents a 3.27% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 3.10% of the company’s stock.

Hedge Funds Weigh In On Intellia Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of NTLA. HRT Financial LP grew its stake in Intellia Therapeutics by 151.1% during the 2nd quarter. HRT Financial LP now owns 221,328 shares of the company’s stock valued at $2,076,000 after acquiring an additional 133,175 shares in the last quarter. BNP Paribas Financial Markets grew its position in Intellia Therapeutics by 25.3% during the second quarter. BNP Paribas Financial Markets now owns 426,667 shares of the company’s stock valued at $4,002,000 after purchasing an additional 86,210 shares in the last quarter. Invesco Ltd. grew its position in Intellia Therapeutics by 47.0% during the second quarter. Invesco Ltd. now owns 251,576 shares of the company’s stock valued at $2,360,000 after purchasing an additional 80,401 shares in the last quarter. Norges Bank purchased a new position in Intellia Therapeutics during the second quarter valued at approximately $534,000. Finally, AQR Capital Management LLC grew its position in Intellia Therapeutics by 154.1% during the first quarter. AQR Capital Management LLC now owns 90,875 shares of the company’s stock valued at $646,000 after purchasing an additional 55,118 shares in the last quarter. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently commented on NTLA. Royal Bank Of Canada reissued a “sector perform” rating and set a $14.00 price target (down from $21.00) on shares of Intellia Therapeutics in a report on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Intellia Therapeutics in a research note on Wednesday, October 8th. Guggenheim cut shares of Intellia Therapeutics from a “buy” rating to a “neutral” rating in a research note on Monday. Wall Street Zen upgraded shares of Intellia Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, September 6th. Finally, William Blair lowered shares of Intellia Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Monday. Twelve research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $24.95.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.